Based in Switzerland, Vaximm is a startup. Brouky records 1 investor associated with the company.
Vaximm develops next-generation oral cancer immunotherapies based on its proprietary Immune-Enhancer™ technology to activate immune responses against tumors.
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.